Market Overview

Should Gilead Buy Vertex?

Share:
Should Gilead Buy Vertex?

Adam Feuerstein of TheStreet.com on Tuesday discussed the merits of Gilead Sciences, Inc. (NASDAQ: GILD) acquiring Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Tuesday.

Feuerstein highlighted a report from Bernstein analyst Geoff Porges that suggested  Gilead’s “long-term revenue cliff problem” could be solved by purchasing Vertex and “its growing cystic fibrosis drug franchise for $45 billion.”

According to Feuerstein, “Gilead's stock price has significantly underperformed the broader biotech market over the past six months, in part because investors are concerned about increasing competition eroding its most important HIV and hepatitis C drug franchises.”

Related Link: Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals

feursteinvrtx.png

It was anticipated that Gilead stands to lose 30 to 40 percent of its revenue between 2017 and 2021. However, “Gilead also has an enormous stockpile of cash and access to cheap debt with which it can make another transformative acquisition, just like the company did twice before,” the article noted.

Porges felt that the company needed to secure an “incremental $5-7 billion of revenue to reassure investors about their future outlook,” and that an acquisition would also need to provide “optionality for even higher revenue.”

Feuerstein observed that the acquiring company in such deals often sees its stock fall on news of a large acquisitio; However, in this case, the stock could rise as investors anticipate a higher earnings multiple that would be “on par with other profitable biotech and drug companies.”

Shares of Gilead Sciences recently traded at $104.67, up 3.99 percent.

Vertex Pharmaceuticals also traded higher, up 5.38 percent at $132.31.

Posted-In: Adam Feuerstein Bernstein Geoff Porges TheStreet.comM&A Rumors Media Best of Benzinga

 

Related Articles (GILD + VRTX)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial
Book A Demo

Top Performing Industries For April 21, 2015

BoA Initiates Coverage On New Residential And Sees 20% Upside